LCGC
CUE icon

Legacy Capital Group California’s Cue Biopharma CUE Stock Holding History

Legacy Capital Group California’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-333
Closed -$7.57K – 337
2024
Q3 		$7.57K Hold
333
– – ﹤0.01% 312
2024
Q2 		$12.4K Hold
333
– – ﹤0.01% 307
2024
Q1 		$18.9K Hold
333
– – 0.01% 300
2023
Q4 		$26.4K Buy
+333
New +$23.8K 0.01% 272

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Legacy Capital Group California's CUE Position: Q4 2024 in Review

Legacy Capital Group California sold out of Cue Biopharma (CUE) in Q4 2024, closing a stake of 333 shares — an estimated $7.57K sold.

Legacy Capital Group California first reported a position in CUE in Q4 2023 and held it in 4 quarters. The position peaked at $26.4K in Q4 2023. 54 funds tracked by Wall St. Rank hold CUE as of Q4 2024.

  • Legacy Capital Group California reported no remaining Cue Biopharma position as of Q4 2024 after selling out during the quarter.
  • Legacy Capital Group California sold 333 Cue Biopharma shares in Q4 2024, an estimated $7.57K.
  • Legacy Capital Group California first reported a position in Cue Biopharma in Q4 2023 and held it in 4 quarters.
  • Legacy Capital Group California's Cue Biopharma position peaked at $26.4K in Q4 2023.
  • 54 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2024.

Based on Legacy Capital Group California's 13F filing for Q4 2024, filed 3 Feb 2025.